The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
A Comprehensive Overview of Globally Approved JAK Inhibitors
Open accessAbstract
Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several genes involved in inflammatory, immune, and cancer conditions. Targeting the JAK family kinases with small-molecule inhibitors has proved to be effective in the treatment of different types of diseases. In the current review, eleven of the JAK inhibitors that received approval for clinical use have been discussed. These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. The aim of the current review was to provide an integrated overview of the chemical and pharmacological data of the globally approved JAK inhibitors. The synthetic routes of the eleven drugs were described. In addition, their inhibitory activities against different kinases and their pharmacological uses have also been explained. Moreover, their crystal structures with different kinases were summarized, with a primary focus on their binding modes and interactions. The proposed metabolic pathways and metabolites of these drugs were also illustrated. To sum up, the data in the current review could help in the design of new JAK inhibitors with potential therapeutic benefits in inflammatory and autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines, Inflammation, and Pain
Zhang, J.-M., & An, J. (2007) · International Anesthesiology Clinics · doi:10.1097/aia.0b013e318034194e · Cited by 2,945
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,835
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206 · cited 2×
“The four JAKs play an essential role in the transduction of the cytokine-mediated signals, which takes place through the JAK-signal transducers and activators of the transcription (STAT) pathway [3].”
BackgroundPlacebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,024
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 695
Yamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O'Shea, J. J. (2004) · Genome Biology · doi:10.1186/gb-2004-5-12-253 · Cited by 635
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M. H., Cohen, S., Nash, P., Song, Y., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37816 · Cited by 577
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Mease, P., Hall, S., FitzGerald, O., van der Heijde, D., Merola, J. F., Avila-Zapata, F., Cieślak, D., Graham, D., Wang, C., Menon, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615975 · Cited by 571
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516
Wallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31363-1 · Cited by 513
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Gladman, D., Rigby, W., Azevedo, V. F., Behrens, F., Blanco, R., Kaszuba, A., Kudlacz, E., Wang, C., Menon, S., Hendrikx, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615977 · Cited by 510
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., Kataoka, Y., Chu, C.-Y., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 476
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470 · cited 2×
“Several ligands such as cytokines and growth factors have been reported to activate the JAK-STAT pathway [10].”
BackgroundFeagan, B. G., Danese, S., Loftus, E. V., Vermeire, S., Schreiber, S., Ritter, T., Fogel, R., Mehta, R., Nijhawan, S., Kempiński, R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00666-8 · Cited by 462
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 435
Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction
Wilks, A. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.5.1603 · Cited by 424
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5818 · Cited by 399
Wernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.009 · Cited by 390
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
BMP signaling in skeletal development
Wan, M., & Cao, X. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.067 · Cited by 383
Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., Tokarski, J. S., Strnad, J., Zupa-Fernandez, A., Cheng, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00444 · Cited by 382
Smolen, J. S., Pangan, A. L., Emery, P., Rigby, W., Tanaka, Y., Vargas, J. I., Zhang, Y., Damjanov, N., Friedman, A., Othman, A. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30419-2 · Cited by 379
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317
Papp, K., Szepietowski, J. C., Kircik, L., Toth, D., Eichenfield, L. F., Leung, D. Y. M., Forman, S. B., Venturanza, M. E., Sun, K., Kuligowski, M. E., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.085 · Cited by 313
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
McInnes, I. B., Anderson, J. K., Magrey, M., Merola, J. F., Liu, Y., Kishimoto, M., Jeka, S., Pacheco-Tena, C., Wang, X., Chen, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2022516 · Cited by 312
Burke, J. R., Cheng, L., Gillooly, K. M., Strnad, J., Zupa-Fernandez, A., Catlett, I. M., Zhang, Y., Heimrich, E. M., McIntyre, K. W., Cunningham, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1736 · Cited by 289
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 281
Dowty, M. E., Lin, J., Ryder, T. F., Wang, W., Walker, G. S., Vaz, A., Chan, G. L., Krishnaswami, S., & Prakash, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054940 · Cited by 279
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2413 · Cited by 266
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 264
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
Mascarenhas, J., & Hoffman, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3145 · Cited by 250
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242 · cited 1×
“Delgocitinib displayed therapeutic efficacy in the treatment of patients with atopic dermatitis [98].”
BackgroundWesthovens, R., Taylor, P. C., Alten, R., Pavlova, D., Enríquez-Sosa, F., Mazur, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210104 · Cited by 236
Van Rompaey, L., Galien, R., van der Aar, E. M., Clement-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 231
Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.020 · Cited by 227
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226
Ember, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 221
The regulation of JAKs in cytokine signaling and its breakdown in disease
Hammarén, H. M., Virtanen, A. T., Raivola, J., & Silvennoinen, O. (2019) · Cytokine · doi:10.1016/j.cyto.2018.03.041 · Cited by 217
Angelini, J., Talotta, R., Roncato, R., Fornasier, G., Barbiero, G., Dal Cin, L., Brancati, S., & Scaglione, F. (2020) · Biomolecules · doi:10.3390/biom10071002 · Cited by 213
Pardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E., & Tefferi, A. (2009) · Leukemia · doi:10.1038/leu.2009.50 · Cited by 207
Telliez, J.-B., Dowty, M. E., Wang, L., Jussif, J., Lin, T., Li, L., Moy, E., Balbo, P., Li, W., Zhao, Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00677 · Cited by 204
William, A. D., Lee, A. C.-H., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Tan, E., Chen, D., Williams, M., Sun, E. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200326p · Cited by 201
Mease, P., Coates, L. C., Helliwell, P. S., Stanislavchuk, M., Rychlewska-Hanczewska, A., Dudek, A., Abi-Saab, W., Tasset, C., Meuleners, L., Harrison, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32483-8 · Cited by 196
Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216677 · Cited by 194
Self-citationTalpaz, M., & Kiladjian, J.-J. (2021) · Leukemia · doi:10.1038/s41375-020-0954-2 · Cited by 188
Baricitinib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0723-3 · Cited by 186
Lin, Q., Meloni, D., Pan, Y., Xia, M., Rodgers, J., Shepard, S., Li, M., Galya, L., Metcalf, B., Yue, T.-Y., et al. (2009) · Organic Letters · doi:10.1021/ol900350k · Cited by 171
Vazquez, M. L., Kaila, N., Strohbach, J. W., Trzupek, J. D., Brown, M. F., Flanagan, M. E., Mitton-Fry, M. J., Johnson, T. A., TenBrink, R. E., Arnold, E. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01598 · Cited by 169
Eichenfield, L. F., Flohr, C., Sidbury, R., Siegfried, E., Szalai, Z., Galus, R., Yao, Z., Takahashi, H., Barbarot, S., Feeney, C., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.2830 · Cited by 169
Deep learning identifies synergistic drug combinations for treating COVID-19
Jin, W., Stokes, J. M., Eastman, R. T., Itkin, Z., Zakharov, A. V., Collins, J. J., Jaakkola, T. S., & Barzilay, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105070118 · Cited by 169
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
Vainchenker, W., Leroy, E., Gilles, L., Marty, C., Plo, I., & Constantinescu, S. N. (2018) · F1000Research · doi:10.12688/f1000research.13167.1 · Cited by 163
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Nogueira, M., Puig, L., & Torres, T. (2020) · Drugs · doi:10.1007/s40265-020-01261-8 · Cited by 162
Blauvelt, A., Silverberg, J. I., Lynde, C. W., Bieber, T., Eisman, S., Zdybski, J., Gubelin, W., Simpson, E. L., Valenzuela, F., Criado, P. R., et al. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.05.075 · Cited by 159
Selective JAK inhibitors in development for rheumatoid arthritis
Norman, P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.918604 · Cited by 158
Family-wide Structural Analysis of Human Numb-Associated Protein Kinases
Sorrell, F. J., Szklarz, M., Azeez, K. R. A., Elkins, J. M., & Knapp, S. (2016) · Structure · doi:10.1016/j.str.2015.12.015 · Cited by 155
Therapeutic Targeting of the JAK / STAT Pathway
Aittomäki, S., & Pesu, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12164 · Cited by 152
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
STATs: An Old Story, Yet Mesmerizing.
Abroun, S., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2015) · PubMed Central · doi:10.22074/cellj.2015.1 · Cited by 152
The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
Ferrao, R., & Lupardus, P. J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00071 · Cited by 150
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Andraos, R., Qian, Z., Bonenfant, D., Rubert, J., Vangrevelinghe, E., Scheufler, C., Marque, F., Régnier, C. H., Pover, A. D., Ryckelynck, H., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0324 · Cited by 144
Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
Wu, S.-C., Li, L. S., Kopp, N., Montero, J., Chapuy, B., Yoda, A., Christie, A. L., Liu, H., Christodoulou, A. N., van Bodegom, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.005 · Cited by 135
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
Singer, J. W., Al‐Fayoumi, S., Ma, H., Komrokji, R. S., Mesa, R. A., & Verstovšek, S. (2016) · Journal of Experimental Pharmacology · doi:10.2147/jep.s110702 · Cited by 135
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof
Davis, R. R., Li, B., Yun, S. Y., Chan, A., Nareddy, P. R., Gunawan, S., Ayaz, M., Lawrence, H. R., Reuther, G. W., Lawrence, N. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01952 · Cited by 135
Duggan, S. T., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01211-z · Cited by 134
Haydl, A. M., Xu, K., & Breit, B. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501758 · Cited by 132
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
Nielsen, C. M., Birgens, H., Nordestgaard, B. G., Kjær, L., & Bojesen, S. E. (2010) · Haematologica · doi:10.3324/haematol.2010.033191 · Cited by 131
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Menet, C. J., Fletcher, S. R., Lommen, G. V., Geney, R., Blanc, J., Smits, K., Jouannigot, N., Deprez, P., van der Aar, E. M., Clément-Lacroix, P., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501262q · Cited by 131
Jak3 and the pathogenesis of severe combined immunodeficiency
OASHEA, J. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.04.014 · Cited by 130
Genovese, M. C., van Vollenhoven, R., Pacheco‐Tena, C., Zhang, Y., & Kinnman, N. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39473 · Cited by 130
Zhou, T., Georgeon, S., Moser, R., Moore, D. J., Caflisch, A., & Hantschel, O. D. (2013) · Leukemia · doi:10.1038/leu.2013.205 · Cited by 126
Forster, M., Chaikuad, A., Bauer, S. M., Holstein, J., Robers, M. B., Corona, C. R., Gehringer, M., Pfaffenrot, E., Ghoreschi, K., Knapp, S., et al. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.10.008 · Cited by 126
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01291-2 · Cited by 126 · cited 10×
“Delgocitinib (Figure 22) is a pan-JAK inhibitor that was approved for atopic dermatitis in 2020 in Japan [69].”
BackgroundInfluentialSTATs: An Old Story, Yet Mesmerizing
Saeid, A., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 124
Development of Selective Covalent Janus Kinase 3 Inhibitors
Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00710 · Cited by 122
Shi, J. G., Chen, X., Emm, T. A., Scherle, P., McGee, R. F., Lo, Y. Y. C., Landman, R. R., McKeever, E., Punwani, N. G., Williams, W. V., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405663 · Cited by 121
Deeks, E. D., & Duggan, S. T. (2021) · Drugs · doi:10.1007/s40265-021-01638-3 · Cited by 120
Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 119
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Hart, S., Goh, K. C., Novotny‐Diermayr, V., Tan, Y., Madan, B., Amalini, C., Ong, L. C., Kheng, B., Cheong, A., Zhou, J., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.43 · Cited by 118
Min, X., Ungureanu, D., Maxwell, S. S., Hammarén, H. M., Thibault, S., Hillert, E., Ayres, M., Greenfield, B., Eksterowicz, J. E., Gabel, C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672048 · Cited by 116
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
Kilpivaara, O., & Levine, R. L. (2008) · Leukemia · doi:10.1038/leu.2008.229 · Cited by 115
Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Shilling, A. D., Nedza, F. M., Emm, T., Diamond, S., McKeever, E., Punwani, N., Williams, W., Arvanitis, A., Galya, L. G., Li, M., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033787 · Cited by 111
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 111
Worm, M., Bauer, A., Elsner, P. U., Mahler, V., Molin, S., & Nielsen, T. S. S. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18469 · Cited by 108
Blair, H. A. (2019) · Drugs · doi:10.1007/s40265-019-01205-x · Cited by 107
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Goedken, E. R., Argiriadi, M. A., Banach, D. L., Fiamengo, B. A., Foley, S. E., Frank, K. E., George, J. S., Harris, C. M., Hobson, A. D., Ihle, D. C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595181 · Cited by 101
Thoma, G., Nuninger, F., Falchetto, R. A., Hermes, E., Tavares, G., Vangrevelinghe, E., & Zerwes, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101157q · Cited by 100
Leroy, E., & Constantinescu, S. N. (2017) · Leukemia · doi:10.1038/leu.2017.43 · Cited by 99
Schroeder, M. A., Khoury, H. J., Jagasia, M., Ali, H., Schiller, G. J., Staser, K. W., Choi, J., Gehrs, L., Arbushites, M. C., Yan, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001043 · Cited by 98
Ito, M., Yamazaki, S., Yamagami, K., Kuno, M., Morita, Y., Okuma, K., Nakamura, K., Chida, N., Inami, M., Inoue, T., et al. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.001 · Cited by 96
Peficitinib: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01131-y · Cited by 96
Verstovšek, S., Odenike, O. M., Singer, J. W., Granston, T., Al‐Fayoumi, S., & Deeg, H. J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0367-x · Cited by 92
Genovese, M. C., Greenwald, M., Codding, C. E., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40054 · Cited by 92
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
Chang, Y., Min, J., Jarusiewicz, J., Actis, M., Bradford, S. Y. C., Mayasundari, A., Yang, L., Chepyala, D., Alcock, L. J., Roberts, K. G., et al. (2021) · Blood · doi:10.1182/blood.2020006846 · Cited by 91
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Yi, C. A., Tam, C. S. L., & Verstovšek, S. (2015) · Future Oncology · doi:10.2217/fon.14.272 · Cited by 88
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
Casimiro‐Garcia, A., Trujillo, J. I., Vajdos, F. F., Juba, B. M., Banker, M. E., AULABAUGH, A. E., Balbo, P., Bauman, J. N., Chrencik, J., Coe, J. W., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01308 · Cited by 87
Hamaguchi, H., Amano, Y., Moritomo, A., Shirakami, S., Nakajima, Y., Nakai, K., Nomura, N., Ito, M., Higashi, Y., & Inoue, T. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.005 · Cited by 86
Dhillon, S., & Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01439-0 · Cited by 86
Xu, P., Shen, P., Yu, B., Xu, X. J., Ge, R., Cheng, X., Chen, Q., Bian, J., Li, Z., & Wang, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112155 · Cited by 85
Vanhoutte, F. P., Mazur, M., Voloshyn, O. I., Stanislavchuk, M., der Aa, A. V., Namour, F., Galien, R., Meuleners, L., & Klooster, G. A. E. V. '. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40186 · Cited by 83
Advances in the Discovery of Selective JAK Inhibitors
Menet, C. J., Rompaey, L. V., & Geney, R. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00004-1 · Cited by 80
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Bryan, M. C., & Rajapaksa, N. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00667 · Cited by 77
Mohamed, M. F., Klünder, B., & Othman, A. A. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00855-0 · Cited by 77
Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis
Yasuda, T., Fukada, T., Nishida, K., Nakayama, M., Matsuda, M., Miura, I., Dainichi, T., Fukuda, S., Kabashima, K., Nakaoka, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82887 · Cited by 76
Minshawi, F., Lanvermann, S., McKenzie, E. A., Jeffery, R., Couper, K. N., Papoutsopoulou, S., Roers, A., & Müller, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01794 · Cited by 76
JAK1 inhibition and inflammatory bowel disease
Harris, C., & Cummings, F. J. R. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa896 · Cited by 76
Upadacitinib for the treatment of rheumatoid arthritis
Serhal, L., & Edwards, C. J. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1544892 · Cited by 75
Mohamed, M. F., Jungerwirth, S., Asatryan, A., Jiang, P. X., & Othman, A. A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13329 · Cited by 72
Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors
Garrido-Trigo, A., & Salas, A. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz206 · Cited by 70
Jensen, K. V., Cseh, O., Aman, A. M., Weiss, S., & Luchman, H. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189670 · Cited by 69
The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog
Collard, W. T., Hummel, B. D., Fielder, A. F., King, V. L., Boucher, J. F., Mullins, M., Malpas, P. B., & Stegemann, M. R. (2013) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12087 · Cited by 68
Selective Janus kinase inhibitors come of age
O’Shea, J. J., & Gadina, M. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0155-9 · Cited by 68
Noji, S., Hara, Y., Miura, T., Yamanaka, H., Maeda, K., Hori, A., Yamamoto, H., Obika, S., Inoue, M., Hase, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00450 · Cited by 68
Hosseini, M. M., Kurtz, S. E., Abdelhamed, S., Mahmood, S., Davare, M. A., Kaempf, A., Elferich, J., McDermott, J. E., Liu, T., Payne, S. H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0112-2 · Cited by 65
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
Coricello, A., Mesiti, F., Lupia, A., Maruca, A., & Alcaro, S. (2020) · Molecules · doi:10.3390/molecules25153321 · Cited by 62
Synthetic Approaches to the New Drugs Approved during 2019
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Mahapatra, S., Carney, D. W., Lindsey, E. A., DeForest, J. C., France, S. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00208 · Cited by 60
Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic
Tavallai, M., Booth, L. A., Roberts, J. L., Poklepovic, A. S., & Dent, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00142 · Cited by 58
Ma, J., Xing, W., Coffey, G., Dresser, K., Lu, K., Guo, A., Raca, G., Pandey, A., Conley, P. B., Yu, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6316 · Cited by 57
Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis
Huang, Z., Lee, P. Y., Yao, X., Zheng, S., & LI, T. W. (2019) · PEDIATRICS · doi:10.1542/peds.2018-2845 · Cited by 56
Namour, F., Desrivot, J., der Aa, A. V., Harrison, P., Tasset, C. T., & Klooster, G. A. E. V. '. (2016) · Drug Metabolism Letters · doi:10.2174/1872312810666151223103353 · Cited by 55
Banović, F., Tarigo, J. L., Gordon, H., Barber, J. P., & Gogal, R. M. (2018) · Veterinary Dermatology · doi:10.1111/vde.12698 · Cited by 52
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Alexander, M. T., Luo, Y., Raimondi, G., O’Shea, J. J., & Gadina, M. (2021) · Pharmaceuticals · doi:10.3390/ph15010048 · Cited by 51
Nakagawa, H., Nemoto, O., Yamada, H., Nagata, T., & Ninomiya, N. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14322 · Cited by 49
Singh, D., Bogus, M., Moskalenko, V., Lord, R. W., Moran, E. J., Crater, G., Bourdet, D. L., Pfeifer, N. D., Woo, J., Kaufman, E., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00673-2021 · Cited by 48
Verstovšek, S., Mesa, R. A., Salama, M. E., Li, L., Pitou, C., Nunes, F. P., Price, G. L., Giles, J. L. K., D’Souza, D. N., Walgren, R. A., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.08.010 · Cited by 47
Musumeci, F., Greco, C., Giacchello, I., Fallacara, A. L., Ibrahim, M. M., Grossi, G., Brullo, C., & Schenone, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180327093502 · Cited by 46
Burmester, G. R., Winthrop, K. L., Blanco, R., Nash, P. T., Goupille, P., Azevedo, V. F., Salvarani, C., Rubbert‐Roth, A., Lesser, E., Lippe, R., et al. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00410-z · Cited by 45
Jeon, J. Y., Zhao, Q., Buelow, D. R., Phelps, M. A., Walker, A. R., Mims, A. S., Vasu, S., Behbehani, G. K., Blachly, J. S., Blum, W. G., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00786-4 · Cited by 43
Yang, T., Hu, M., Qi, W., Yang, Z., Tang, M., He, J., Chen, Y. X., Bai, P., Yuan, X., Zhang, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01348 · Cited by 41
Rheumatoid arthritis in Saudi Arabia
Almoallim, H. M., & Alharbi, L. A. (2014) · Saudi Medical Journal · doi:10.15537/1658-3175.6095 · Cited by 40
Degryse, S., Bornschein, S., de Bock, C. E., Leroy, E., Bempt, M. V., Demeyer, S., Jacobs, K., Geerdens, E., Gielen, O., Soulier, J., et al. (2017) · Blood · doi:10.1182/blood-2017-07-797597 · Cited by 40
Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials
Tanaka, Y., & Izutsu, H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1739649 · Cited by 39
Kostik, M. M., Raupov, R. K., Suspitsin, E. N., Isupova, E. A., Gaidar, E. V., Gabrusskaya, T. V., Kaneva, M. A., Snegireva, L. S., Likhacheva, T. S., Mulkidzhan, R., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.820586 · Cited by 39
Muensterman, E. T., Engelhardt, B., Gopalakrishnan, S., Anderson, J. K., & Mohamed, M. F. (2021) · Clinical and Translational Science · doi:10.1111/cts.13146 · Cited by 38
c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
Duan, Y., Chen, L., Chen, Y., & Fan, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106225 · Cited by 37
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
Wang, E. Q., Le, V., O’Gorman, M. T., Tripathy, S., Dowty, M. E., Wang, L., & Malhotra, B. K. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1858 · Cited by 37
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry
Séror, R., Camus, M., Salmon, J.-H., Roux, C. H., Dernis, E., Basch, A., Germain, V., Leske, C., Brousseau, S., Truchetet, M., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00314-3 · Cited by 37
Rationales and uncertainties for aspirin use in COVID-19: a narrative review
Ahmed, H. A. S., Merrell, E., Ismail, M., Joudeh, A. I., Riley, J. B., Shawkat, A., Habeb, H., Darling, E., Goweda, R. A., Shehata, M. H., et al. (2021) · Family Medicine and Community Health · doi:10.1136/fmch-2020-000741 · Cited by 35
Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis
Wood, H., Chandler, A., Nezamololama, N., Papp, K. A., & Gooderham, M. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15853 · Cited by 33
Connor, C. G., DeForest, J. C., Dietrich, P., Do, N. M., Doyle, K. M., Eisenbeis, S. A., Greenberg, E., Griffin, S. H., Jones, B. P., Jones, K. N., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00366 · Cited by 29
Izumo, T., Kuse, N., Awano, N., Tone, M., Sakamoto, K., Takada, K., Muto, Y., Fujimoto, K., Saiki, A., Ito, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.07.004 · Cited by 29
Tofacitinib for the treatment of active ankylosing spondylitis in adults
Mohanakrishnan, R., Beier, S., & Deodhar, A. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2038134 · Cited by 28
An Efficient Synthesis of Baricitinib
Xu, J., Cai, J., Chen, J., Zong, X., Wu, X., Ji, M., & Wang, P. G. (2016) · Journal of Chemical Research · doi:10.3184/174751916x14569294811333 · Cited by 25
Strand, V., Mease, P. J., Soriano, E. R., Kishimoto, M., Salvarani, C., Saffore, C. D., Zueger, P., McDearmon-Blondell, E. L., Kato, K., & Gladman, D. D. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00379-9 · Cited by 25
Fensome, A., Ambler, C. M., Arnold, E. P., Banker, M. E., Clark, J. D., Dowty, M. E., Efremov, I. V., Flick, A. C., Gerstenberger, B. S., Gifford, R. S., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115481 · Cited by 24
Additional baricitinib loading dose improves clinical outcome in COVID-19
Hasan, M. J., Rabbani, R., Anam, A. M., & Huq, S. M. R. (2020) · Open Medicine · doi:10.1515/med-2021-0010 · Cited by 24
Oda, K., Cao, Y. J., Sawamoto, T., Nakada, N., Fisniku, O., Nagasaka, Y., & Sohda, K. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1026864 · Cited by 23
FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms
Poubel, C. P., Mansur, M. B., Boroni, M., & Emerenciano, M. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.06.001 · Cited by 20
Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1
Liau, N. P. D., Laktyushin, A., Morris, R., Sandow, J. J., Nicola, N. A., Kershaw, N. J., & Babon, J. J. (2019) · Cancers · doi:10.3390/cancers11111701 · Cited by 20
Abourehab, M. A. S., Alqahtani, A. M., Almalki, F. A., Zaher, D. M., Abdalla, A. N., Gouda, A. M., & Beshr, E. A. M. (2021) · Molecules · doi:10.3390/molecules26216582 · Cited by 19
Self-citationRynhoud, H., Gibson, J. S., Meler, E. N., & Magalhães, R. J. S. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.631443 · Cited by 18
Filgotinib for the treatment of Crohn’s disease
Labetoulle, R., Paul, S., & Roblin, X. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442433 · Cited by 17
Under Development JAK Inhibitors for Dermatologic Diseases
Sideris, N., Vakirlis, E., Tsentemeidou, A., Kourouklidou, A., Ioannides, D., & Sotiriou, E. (2020) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.31.1.137 · Cited by 17
Almalki, F. A., Shawky, A. M., Abdalla, A. N., & Gouda, A. M. (2021) · Molecules · doi:10.3390/molecules26216423 · Cited by 17
Self-citationMyelofibrosis, JAK2 inhibitors and erythropoiesis
Vainchenker, W., & Favale, F. (2013) · Leukemia · doi:10.1038/leu.2013.72 · Cited by 16
Comparing available JAK inhibitors for treating patients with psoriasis
Funk, P. J., Perche, P. O., Singh, R., Kelly, K. A., & Feldman, S. R. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2039121 · Cited by 16
Chamberlain, P. P., Delker, S. L., Pagarigan, B., Mahmoudi, A., Jackson, P. J., Abbasian, M., Jeff, M., Raheja, N., & Cathers, B. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103638 · Cited by 15
Stereocontrolled Synthesis of Delgocitinib, a JAK Inhibitor for the Treatment of Atopic Dermatitis
Takiguchi, H., Higashi, A., Watanabe, T., Takeichi, T., Shimazaki, T., & Inaba, T. (2021) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00031 · Cited by 15
Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib
Haugh, I. M., Watson, I., & Menter, A. (2018) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2018.1480246 · Cited by 14
JAK1 somatic mutation in a myeloproliferative neoplasm
Arulogun, S. O., Choong, H.-L., Taylor, D., Ambrosoli, P., Magor, G. W., Irving, I., Keng, T. B., & Perkins, A. C. (2017) · Haematologica · doi:10.3324/haematol.2017.170266 · Cited by 13
Ogasawara, K., Xu, C. R., Kanamaluru, V., Siebers, N., Surapaneni, S., Ridoux, L., Palmisano, M., & Krishna, G. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04121-0 · Cited by 12
Miyatake, D., Shibata, T., Toyoshima, J., Kaneko, Y., Oda, K., Nishimura, T., Katashima, M., Sakaki, M., Inoue, K., Ito, T., et al. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.751 · Cited by 11
Bergman, M. J., Tundia, N. L., Yang, M. H., Orvis, E., Clewell, J., & Bensimon, A. G. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01930-4 · Cited by 8
JAK inhibitors in the treatment of atopic dermatitis
Witkoff, B., Logas, C. M., Glick, B. P., & Rosso, J. Q. D. (2022) · Dermatological Reviews · doi:10.1002/der2.116 · Cited by 4
Cited by
Macrocycles in Drug Discovery─Learning from the Past for the Future
Garcia Jimenez, D., Poongavanam, V., & Kihlberg, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00134 · Cited by 321
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
Galbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., Worek, K., Granrath, R. E., Kinning, K. T., Paul Eduthan, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg6218 · Cited by 88
JAK inhibition decreases the autoimmune burden in Down syndrome
Rachubinski, A. L., Wallace, E., Gurnee, E., Enriquez-Estrada, B. A., Worek, K. R., Smith, K. P., Araya, P., Waugh, K. A., Granrath, R. E., Britton, E., et al. (2024) · eLife · doi:10.7554/elife.99323 · Cited by 32
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116220 · Cited by 18
Metadata
- Authors
- Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-05-06
- Volume
- 14
- Issue
- 5
- Pages
- 1001
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4229366062
- Cited by
- 349
- References
- 185
- FWCI
- 24.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.